SITC 2024: Aulos Bioscience CEO Aron Knickerbocker describes the phase 1 and preliminary phase 2 data for the company's IL-2 redirecting antibody
He describes the safety and preliminary efficacy they have seen, including how patients are experiencing a lowering of Tregs. Plus, the future of the therapy in melanoma, lung cancer, and beyond.